Cited by 166Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease PreventionFolate and B Vitamins Research

Systemic and Vascular Oxidation Limits the Efficacy of Oral Tetrahydrobiopterin Treatment in Patients With Coronary Artery Disease

Open access
Cunnington, Colin, Van Assche, Tim, Shirodaria, Cheerag, Kylintireas, Ilias, Lindsay, Alistair C., Lee, Justin M., Antoniades, Charalambos, Margaritis, Marios +10 more·2012·Circulation

Abstract

Background—: The endothelial nitric oxide synthase cofactor tetrahydrobiopterin (BH4) plays a pivotal role in maintaining endothelial function in experimental vascular disease models and in humans. Augmentation of endogenous BH4 levels by oral BH4 treatment has been proposed as a potential therapeutic strategy in vascular disease states. We sought to determine the mechanisms relating exogenous BH4 to human vascular function and to determine oral BH4 pharmacokinetics in both plasma and vascular tissue in patients with coronary artery disease. Methods and Results—: Forty-nine patients with coronary artery disease were randomized to receive low-dose (400 mg/d) or high-dose (700 mg/d) BH4 or placebo for 2 to 6 weeks before coronary artery bypass surgery. Vascular function was quantified by magnetic resonance imaging before and after treatment, along with plasma BH4 levels. Vascular superoxide, endothelial function, and BH4 levels were determined in segments of saphenous vein and internal mammary artery. Oral BH4 treatment significantly augmented BH4 levels in plasma and in saphenous vein (but not internal mammary artery) but also increased levels of the oxidation product dihydrobiopterin (BH2), which lacks endothelial nitric oxide synthase cofactor activity. There was no effect of BH4 treatment on vascular function or superoxide production. Supplementation of human vessels and blood with BH4 ex vivo revealed rapid oxidation of BH4 to BH2 with predominant BH2 uptake by vascular tissue. Conclusions—: Oral BH4 treatment augments total biopterin levels in patients with established coronary artery disease but has no net effect on vascular redox state or endothelial function owing to systemic and vascular oxidation of BH4. Alternative strategies are required to target BH4-dependent endothelial function in established vascular disease states. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00423280.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.038919

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Oral BH4 for 2-6 wk in patients with coronary artery disease did not show improvement and increased BH2 levels.

    “A treatment with oral BH4 for 2–6 wk in patients with coronary artery disease did not show improvement; and actually increased BH2 levels (202).”
  • In most examples, BH4 improves endothelial function, but in some conditions BH4 supplementation is not a practical therapeutic approach.

    “In most examples, BH4 is able to improve endothelial function, but the study by Cunnington et al. (202) clearly indicated that in some conditions, BH4 supplementation is not a practical therapeutic approach.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cunnington, C., Van Assche, T., Shirodaria, C., Kylintireas, I., Lindsay, A. C., Lee, J. M., Antoniades, C., Margaritis, M., Lee, R., Cerrato, R., Crabtree, M. J., Francis, J. M., Sayeed, R., Ratnatunga, C., Pillai, R., Choudhury, R. P., Neubauer, S., & Channon, K. M.
Affiliations
  • John Radcliffe Hospital (GB)
  • From the Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Venue
Circulation
Published
2012-03-20
Volume
125
Issue
11
Pages
1356-1366
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1987686985
Cited by
166
References
31
Citations by year
2026: 5 · 2025: 9 · 2024: 3 · 2023: 12 · 2022: 7 · 2021: 12 · 2020: 8 · 2019: 9 · 2018: 12 · 2017: 13 · 2016: 10 · 2015: 19 · 2014: 16 · 2013: 14 · 2012: 16
FWCI
13.93
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Wellcome Trust (088291, 090532)
  • National Institute for Health and Care Research (NF-SI-0508-10247, IS-BRC-0211-10025)
  • British Heart Foundation (RG/07/003/23133, PG/08/119/26263, RG/12/5/29576)
Topics
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Medicine › Rheumatology › Folate and B Vitamins Research
Keywords
tetrahydrobiopterin, BH4, dihydrobiopterin, endothelial nitric oxide synthase, coronary artery disease, endothelial function, saphenous vein, internal mammary artery
MeSH terms
Administration, Oral, Aged, Biopterins, Coronary Artery Disease, Double-Blind Method, Endothelium, Vascular, Female, Humans, Male, Oxidation-Reduction, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review